Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

192.87 -0.58 (-0.30%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
74 75 Next >
Wall Street Favorites: 3 Retirement Stocks With Strong Buy Ratings for May 2024
Amid the strong run in the market, investors thinking about long-term goals should consider these strongly endorsed retirement stocks to buy. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
Unpacking the Latest Options Trading Trends in AbbVie
Via Benzinga
3 Magnificent Stocks That Are Passive Income Machines
These three companies have track records that should please investors. 
Via The Motley Fool
What Is the Dividend Payout for AbbVie Stock?
The pharmaceutical company isn't just a quality healthcare holding. It's a compelling income investment as well. 
Via The Motley Fool
(ABBV) - Analyzing AbbVie's Short Interest
Via Benzinga
3 Reasons to Buy AbbVie Stock on the Dip
A little patience with the drugmaker should pay off. 
Via The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today
Via Benzinga
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
Via Benzinga
Healthcare And Biotech Investing 101: What You Need To Know.
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Earn $1000 Every Month From These 3 Stocks
All 3 companies pay growing dividends. 
Via The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
These pharmaceutical companies are top-notch dividend growth stocks for the future. 
Via The Motley Fool
3 Rock-Solid Dividend Stocks That Are Ideal for Retirees
These are low-risk stocks with high yields. 
Via The Motley Fool
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy. 
Via InvestorPlace
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
AbbVie Tracking for New Highs in 2024
Future Dividend King AbbVie is tracking for new highs as the shift away from Humira-based business gains momentum with new treatments and acquisitions. 
Via MarketBeat
Topics Earnings
Exposures Financial
3 Biotech Stocks to Double Your Money in the Next 24 Months
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates. 
Via InvestorPlace
MarketBeat Week in Review – 4/29 - 5/3
Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024 
Via MarketBeat
Topics Economy Stocks
Exposures Interest Rates US Equities
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
Safe haven stocks offer stability even during market fall in communication, financials, healthcare, energy and consumer staples. 
Via InvestorPlace
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher
After falling nearly 6% based on concerns about Humira sales, AbbVie stock is recovering, and bullish analyst sentiment is likely to push the stock higher 
Via MarketBeat
Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing
These dividend aristocrat stocks can protect tired consumers from persistent inflation through dividends that outpace recent spikes. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
The company is projected to bring in increasing sales through at least 2029. 
Via Investor's Business Daily
Better Dividend Stock: AbbVie or Johnson & Johnson?
One thing is for sure: Dividend seekers can't go wrong with either. 
Via The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
You'll get dividends and more with these great stocks. 
Via The Motley Fool
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
Investors are struggling to see past the end of Humira's dominance. 
Via The Motley Fool
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
ABBV earnings call for the period ending March 31, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average of $3,500 yearly. 
Via Benzinga
Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?
Strong earnings reports from Alphabet Inc. (NASDAQ:GOOGL) and Microsoft Corp. (NASDAQ:MSFT) have restored positive sentiment in the market, sweeping away fears of increasing risks of stagflation that... 
Via Benzinga
Topics Economy
Exposures Interest Rates
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
ABBV stock results show that AbbVie beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains. 
Via Benzinga
< Previous 1 2
...
11 12 13 14 15 16 17 18 19
...
74 75 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.